Innoviva Inc (INVA)

NASDAQ
14.56
-0.18(-1.22%)
After Hours
14.56
0.00(0.00%)
- Real-time Data
  • Volume:
    399,897
  • Day's Range:
    14.50 - 14.70
  • 52 wk Range:
    13.64 - 20.71

INVA Overview

Prev. Close
14.74
Day's Range
14.5-14.7
Revenue
403.82M
Open
14.65
52 wk Range
13.64-20.71
EPS
1.43
Volume
399,897
Market Cap
1.01B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
847,130
P/E Ratio
11.77
Beta
0.455
1-Year Change
-11.17%
Shares Outstanding
69,705,967
Next Earnings Date
Nov 02, 2022
What is your sentiment on Innoviva?
or
Market is currently closed. Voting is open during market hours.

Innoviva Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Innoviva Inc Analysis

Innoviva Inc Company Profile

Innoviva Inc Company Profile

Employees
5

Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). ANORO ELLIPTA is a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with an LABA, VI. TRELEGY ELLIPTA (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyNeutralSell
Technical IndicatorsBuySellBuyStrong BuyStrong Sell
SummaryStrong BuyNeutralBuyBuyStrong Sell
  • strong undervalued stock
    0